Study Overview: This research is about testing a new treatment called ISB 2001 for a condition called relapsed/refractory multiple myeloma (R/R MM). This is a kind of cancer that affects plasma cells in the bone marrow and is hard to treat with regular methods. Phase 1 means it's the first time this treatment is being tested in humans, and the study is open-label, so both the doctors and patients know what treatment is being given.
Study Details: The study has two parts: dose escalation and dose expansion. The first part finds out the safest dose, and the second part checks if it works well at that dose. Patients stay on the medicine until the cancer gets worse, side effects are too bad, or they choose to stop. Participants need to have good overall health, no severe brain cancer, or infections, and not be pregnant or breastfeeding.
- Participants receive ISB 2001 until disease progresses or they leave the study.
- Requires good health overall and no serious infections or other illnesses.
- Participants must not be pregnant or breastfeeding.
How understandable was the trial content above?
Hard to understand
Easy to understand